METHOD FOR QUANTITATIVE DETERMINATION OF MUTATIONS F317L AND F359V/C OF THE KINASE DOMAIN BCR-ABL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RESISTANT TO THERAPY WITH TYROSINE KINASE INHIBITORS Russian patent published in 2019 - IPC C12N15/00 G01N33/58 C12Q1/6876 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to medical genetics and oncohematology, and aims at quantitative determination of mutations F317L and F359V/C of the BCR-ABL kinase domain in patients suffering chronic myeloid leukemia resistant to tyrosine kinase inhibitors. One stage of PCR is used to determine expression of BCR-ABL^F317L and BCR-ABL^F359V/C. Primers used are a system for determining F317L consisting of a forward primer SEQ ID NO: 1 and reverse specific primers for mutation SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and specific probe SEQ ID NO: 5. Determining expression of F359V/C, BCR-ABL and ABL, using systems consisting of primers and probes. Number of copies of BCR-ABL^F317L and BCR-ABL^F359V/C in samples are determined by calibration curve, which is constructed according to standards with known concentration. BCR-ABL^F317L, BCR-ABL^F359V/C and BCR-ABL expression is calculated relative to control ABL gene by formulas.

EFFECT: invention provides an effective method of determining mutations F317L and F359V/C of the BCR-ABL kinase domain, having higher sensitivity and specificity.

1 cl, 1 dwg